PULMOHEAL™/ ARTIVEDA™ IS CLINICALLY ACTIVE AGAINST MILD AND MODERATE COVID-19.
24. August 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and COVID-19,...
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.
20. April 2021 12:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and...
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
01. März 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...